News FDA finally approves Sandoz's Neulasta biosimilar, but will ... The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.
News Daiichi Sankyo takes Seattle Genetics to court as battle ove... Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen
News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
